Toric AcrySof stays stable in clinical trials

SAN FRANCISCO — A new toric IOL is showing good rotational stability in clinical trials to date, according to a speaker here.

Stephen S. Lane, MD, the medical monitor for trials of the Alcon AcrySof Toric Single-Piece IOL, described results of the trials here at the American Society of Cataract and Refractive Surgery meeting.

Dr. Lane said the shrink-wrap effect that has been noted with earlier non-toric versions of the AcrySof seems to help keep the new toric lens rotationally stable. He noted that rotation of a toric IOL by as little as 30 degrees can cancel out the astigmatic correction built into the lens.

The modified L-shaped haptics of the lens help keep it in position despite the forces of capsular contraction, he said. A series of dots on the optic of the lens aid the surgeon in aligning the astigmatic axis properly during implantation.

Dr. Lane said that in the clinical trials of the AcrySof Toric to date, more than 60 lenses have been implanted, with follow-up of at least 60 to 80 days.

At postop day 1 or 2, all lenses were within 10 degrees of intended axis, and in fact almost all were right on the proper axis, he said. At the 60- to 80-day visit, there was almost no rotational movement. A lens-by-lens comparison of the 1- to 2-day and the 60- to 80-day visit showed little change in axis position, he said.

The greatest amount of axial rotation seen in any lens was 11 degrees, Dr. Lane said. Only one lens decentered, and that was by less than 0.5 mm.

Although he is medical monitor of the AcrySof Toric study, Dr. Lane noted that he has no direct financial interest in the device. Dr. Lane is the incoming president of ASCRS.